TCTMD’s Top 10 Most Popular Stories for July 2022
The most-read articles covered not just research, but also a doctor’s strike in Turkey, a dobutamine shortage, and other news.
TCTMD’s COVID-19 Dispatch was our most-read story in July, with articles focused on issues of concern among physicians, as well as new research, filling out the list. Three of the top stories delved into a countrywide doctors’ strike in Turkey sparked by a cardiologist’s murder, a US dobutamine shortage, and reactions to proposed cuts to reimbursement by the US Centers for Medicare & Medicaid Services (CMS). There’s also a feature story on the outlook for interatrial shunt devices in patients with heart failure with preserved ejection fraction (HFpEF) and an article on an analysis that raises fresh questions about the benefits seen in the REDUCE-IT trial.
1. COVID-19 TCTMD’s Dispatch
We’re curating a list of COVID-19 research and other useful content, and updating it regularly.
The hospital shooting of Ekrem Karakaya is the latest high-profile attack in Turkey, where assaults on physicians are soaring.
With stocks not expected to stabilize until late this year or early next, hospitals should be planning ahead, one expert says.
A short-term solution by Congress would be acceptable, but the “flawed” system needs an overhaul, said Lyndon Box.
A propensity-matched analysis of Impella and IABP outcomes out to 1 year raise “serious concerns,” upping the stakes for RCTs.
The findings are not definitive, but they should be considered when choosing an anticoagulant, Samir Kapadia says.
The thresholds for starting statins are too high and need to more closely align with other international guidelines, say researchers.
REDUCE-LAP HF II dampened some hopes for LA shunts in heart failure, but the field is learning lessons and moving forward.
Three sham-controlled studies, including this US IDE trial, have been positive for the Paradise system. A fourth study flopped.
The placebo group saw rises in Lp-PLA2, IL-6, IL-1β, and other biomarkers. Could this explain the advantage for icosapent ethyl?